- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Asthma
- Atrial Fibrillation
- COVID-19
- Cardiovascular Diseases
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
State of the Industry 2014
Managed care organizations will be remiss if they don’t seriously consider the evolving competitive landscape.
Clearly 2014 will be the pivotal year in health reform. While designing plan products and pricing them correctly was a huge task in 2013, measuring the market response to rates and benefits will be just as much of a challenge throughout 2014.
And leading managed care organizations will be remiss if they don’t seriously consider the evolving competitive landscape. Unique payer/provider partnerships have created new health plans, and Consumer Oriented and Operated Plans (CO-OPs) are actively signing up members. Each market will emerge from 2014 with a distinctly different health reform story to tell.
Ever since the Patient Protection and Affordable Care Act (PPACA) was signed into law, observers from all corners of the country have made predictions on everything from the ultimate cost of reform to the percentage of the uninsured. There’s a mix of optimism and pessimism. What’s striking though is the opportunity to compare their predictions to reality.
A few weeks ago, Managed Healthcare Executive polled readers on their forecast for 2014 and beyond. Nearly 350 readers responded.
This is the sixth year of our survey, and it’s interesting to take a look back.
For example, 26 states are currently opting out of Medicaid expansion. In last year’s survey, 27% of respondents correctly predicted a range of 21 to 30 states opting out. Yet, more readers (31%) predicted just 11 to 20 states would opt out-quite a bit lower than the actual total. But states can change their minds and expand Medicaid at a later date, so there’s more to come on this issue.
Also in last year’s survey, the majority of respondents (78%) predicted state exchanges would not be ready in time for the October 2013 launch and that implementation would be delayed. The administration did indeed carry on with exchanges, even those operated by the federal government.
Soon, we’ll have the initial findings of health reform’s impact on the country, but until then, we’ll continue to predict and analyze based on the information we do have available.
Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health.
Listen
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
